Blog

Home  /  Outputs   /  JA2-WP5   /  Joint Assessment on Vorapaxar (ZONTIVITY™) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)

Joint Assessment on Vorapaxar (ZONTIVITY™) for the reduction of thrombotic cardiovascular events in patients with a history of myocardial infection (MI)

The purpose of the assessment is to evaluate Vorapaxar (ZONTIVITY™) for the reduction of cardiovascular events.

Final version of the assessment was published in June 2015

Below is the documentation provided by the Joint Assessment authoring team

Vorapaxar for the reduction of thrombotic cardivascular events_Rapid REA_Final_Jun 2015